Industry Leaders Panel Discussion:
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology